Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therape...
Saved in:
| Published in | Experimental & molecular medicine Vol. 57; no. 6; pp. 1294 - 1307 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.06.2025
Springer Nature B.V Nature Publishing Group 생화학분자생물학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2092-6413 1226-3613 2092-6413 |
| DOI | 10.1038/s12276-025-01466-5 |
Cover
| Abstract | Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated
ABCB1
expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ–MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the
ABCB1
promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC.
Targeting BRPF1 offers hope against Taxol resistance
Triple-negative breast cancer (TNBC) is a challenging type of breast cancer that lacks targeted treatment options. Researchers aimed to understand why some TNBC cells become resistant to the chemotherapy drug Taxol and focused on the role of a protein called BRPF1 in this resistance. They created Taxol-resistant TNBC cells in the laboratory and found that these cells had high levels of a protein called ABCB1, which helps to pump drugs out of cells. They used advanced techniques to identify key proteins involved in this resistance and discovered that BRPF1, part of a complex that modifies DNA structure, plays a crucial role. By using genetic tools and chemical inhibitors to reduce BRPF1 activity, they found that the resistant cells became more sensitive to Taxol. This suggests that targeting BRPF1 could be a new way to treat resistant TNBC.
This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. |
|---|---|
| AbstractList | Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated
ABCB1
expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ–MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the
ABCB1
promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC.
Targeting BRPF1 offers hope against Taxol resistance
Triple-negative breast cancer (TNBC) is a challenging type of breast cancer that lacks targeted treatment options. Researchers aimed to understand why some TNBC cells become resistant to the chemotherapy drug Taxol and focused on the role of a protein called BRPF1 in this resistance. They created Taxol-resistant TNBC cells in the laboratory and found that these cells had high levels of a protein called ABCB1, which helps to pump drugs out of cells. They used advanced techniques to identify key proteins involved in this resistance and discovered that BRPF1, part of a complex that modifies DNA structure, plays a crucial role. By using genetic tools and chemical inhibitors to reduce BRPF1 activity, they found that the resistant cells became more sensitive to Taxol. This suggests that targeting BRPF1 could be a new way to treat resistant TNBC.
This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. Abstract Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ–MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC. Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ-MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC. Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ–MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC. KCI Citation Count: 0 Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ–MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC.Targeting BRPF1 offers hope against Taxol resistanceTriple-negative breast cancer (TNBC) is a challenging type of breast cancer that lacks targeted treatment options. Researchers aimed to understand why some TNBC cells become resistant to the chemotherapy drug Taxol and focused on the role of a protein called BRPF1 in this resistance. They created Taxol-resistant TNBC cells in the laboratory and found that these cells had high levels of a protein called ABCB1, which helps to pump drugs out of cells. They used advanced techniques to identify key proteins involved in this resistance and discovered that BRPF1, part of a complex that modifies DNA structure, plays a crucial role. By using genetic tools and chemical inhibitors to reduce BRPF1 activity, they found that the resistant cells became more sensitive to Taxol. This suggests that targeting BRPF1 could be a new way to treat resistant TNBC.This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ–MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC. Triple-negative breast cancer (TNBC) is a challenging type of breast cancer that lacks targeted treatment options. Researchers aimed to understand why some TNBC cells become resistant to the chemotherapy drug Taxol and focused on the role of a protein called BRPF1 in this resistance. They created Taxol-resistant TNBC cells in the laboratory and found that these cells had high levels of a protein called ABCB1, which helps to pump drugs out of cells. They used advanced techniques to identify key proteins involved in this resistance and discovered that BRPF1, part of a complex that modifies DNA structure, plays a crucial role. By using genetic tools and chemical inhibitors to reduce BRPF1 activity, they found that the resistant cells became more sensitive to Taxol. This suggests that targeting BRPF1 could be a new way to treat resistant TNBC. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ-MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC.Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment approach. Unfortunately, the development of resistance to chemotherapy poses a considerable challenge, restricting the already limited therapeutic alternatives for recurrent cases. Here, we generated two Taxol-resistant TNBC cell lines with a dose-escalation method to mimic chemotherapy resistance in vitro. These cells exhibited reduced growth rates, altered morphology and evasion of apoptosis. Transcriptome analysis uncovered elevated ABCB1 expression and multidrug-resistant phenotype in these resistant cells. To comprehensively investigate the key epigenetic regulators of Taxol resistance, we conducted chromatin-focused genetic and chemical screens and pinpointed Bromodomain and PHD Finger Containing 1 (BRPF1) as a novel regulator of Taxol resistance. Knockout of BRPF1, the reader protein in the MOZ-MORF histone acetyltransferase complex, but not the other complex members, sensitized resistant cells to Taxol. In addition, BRPF1 inhibitors, PFI-4 and OF-1, in combination with Taxol significantly reduced cell viability. Transcriptome analysis upon BRPF1 loss or inhibition revealed a negative impact on ribosome biogenesis-related gene sets, resulting in a global decrease in protein translation in Taxol-resistant cells. CUT&RUN-qPCR analysis demonstrated that BRPF1 directly binds to the ABCB1 promoter, enhancing its expression toward inducing a multidrug-resistant phenotype. Conversely, knockout or inhibition of BRPF1 leads to decreased ABCB1 expression. Our findings uncover a comprehensive molecular framework, highlighting the pivotal role of epigenetic reader protein BRPF1 in Taxol resistance and providing potential avenues for therapeutic intervention in TNBC. |
| Author | Oppermann, Udo Cingöz, Ahmet Philpott, Martin Cribbs, Adam P. Degirmenci, Nareg Cavga, Ayse Derya Cevatemre, Buse Bagci-Onder, Tugba Yilmaz, Ebru Syed, Hamzah Aksu, Ali Cenk Acilan, Ceyda Yedier-Bayram, Ozlem Esin, Beril Dedeoğlu, Beyza Onder, Tamer T. Lack, Nathan A. |
| Author_xml | – sequence: 1 givenname: Ozlem surname: Yedier-Bayram fullname: Yedier-Bayram, Ozlem organization: Koç University Research Center for Translational Medicine – sequence: 2 givenname: Ahmet orcidid: 0000-0002-1111-7752 surname: Cingöz fullname: Cingöz, Ahmet organization: Koç University Research Center for Translational Medicine – sequence: 3 givenname: Ebru orcidid: 0000-0003-1033-1797 surname: Yilmaz fullname: Yilmaz, Ebru organization: Koç University Research Center for Translational Medicine – sequence: 4 givenname: Ali Cenk surname: Aksu fullname: Aksu, Ali Cenk organization: Koç University Research Center for Translational Medicine – sequence: 5 givenname: Beril surname: Esin fullname: Esin, Beril organization: Koç University Research Center for Translational Medicine – sequence: 6 givenname: Nareg surname: Degirmenci fullname: Degirmenci, Nareg organization: Koç University Research Center for Translational Medicine – sequence: 7 givenname: Ayse Derya surname: Cavga fullname: Cavga, Ayse Derya organization: Koç University Research Center for Translational Medicine, Biostatistics, Bioinformatics and Data Management Core, Koç University Research Center for Translational Medicine – sequence: 8 givenname: Beyza surname: Dedeoğlu fullname: Dedeoğlu, Beyza organization: Koç University Research Center for Translational Medicine – sequence: 9 givenname: Buse orcidid: 0000-0002-0437-6385 surname: Cevatemre fullname: Cevatemre, Buse organization: Koç University Research Center for Translational Medicine, Koç University School of Medicine – sequence: 10 givenname: Hamzah orcidid: 0000-0001-6981-6962 surname: Syed fullname: Syed, Hamzah organization: Koç University Research Center for Translational Medicine, Biostatistics, Bioinformatics and Data Management Core, Koç University Research Center for Translational Medicine, Koç University School of Medicine – sequence: 11 givenname: Martin surname: Philpott fullname: Philpott, Martin organization: Botnar Research Centre, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, National Institute of Health Research Oxford Biomedical Research Unit, University of Oxford – sequence: 12 givenname: Adam P. orcidid: 0000-0001-5288-3077 surname: Cribbs fullname: Cribbs, Adam P. organization: Botnar Research Centre, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, National Institute of Health Research Oxford Biomedical Research Unit, University of Oxford, Oxford Centre for Translational Myeloma Research, University of Oxford – sequence: 13 givenname: Udo surname: Oppermann fullname: Oppermann, Udo organization: Botnar Research Centre, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, National Institute of Health Research Oxford Biomedical Research Unit, University of Oxford, Oxford Centre for Translational Myeloma Research, University of Oxford – sequence: 14 givenname: Nathan A. surname: Lack fullname: Lack, Nathan A. organization: Koç University Research Center for Translational Medicine, Koç University School of Medicine, Vancouver Prostate Centre, University of British Columbia, Department of Medical Pharmacology, Koç University School of Medicine – sequence: 15 givenname: Ceyda orcidid: 0000-0002-8936-3267 surname: Acilan fullname: Acilan, Ceyda organization: Koç University Research Center for Translational Medicine, Koç University School of Medicine – sequence: 16 givenname: Tamer T. orcidid: 0000-0002-2372-9158 surname: Onder fullname: Onder, Tamer T. organization: Koç University Research Center for Translational Medicine, Koç University School of Medicine – sequence: 17 givenname: Tugba orcidid: 0000-0003-3646-2613 surname: Bagci-Onder fullname: Bagci-Onder, Tugba email: tuonder@ku.edu.tr organization: Koç University Research Center for Translational Medicine, Koç University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40583060$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003227360$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNqNkstu1DAUhiNURC_wAiyQJTYIKeBL7DgrVEYURqoEqsraOnGOp24zzmAnA_MOPDSemVJaFojVsezv_Ofy-7g4CEPAonjO6BtGhX6bGOe1KimXJWWVUqV8VBxx2vBSVUwc3DsfFscpXdNMVnX1pDisqNSCKnpU_JxdxWEJow-lG-yUsCMLDDh6SyB0xF7h0lvoSbIRMSTiOwyjdxvy_uLLGSOQCJAR4gJHaHsk66kPGKH1vR83xAdyCT-GvoyYfBohjGSMftVjGXCRa66RtBEhjcRCsBifFo8d9Amf3caT4uvZh8vZp_L888f57PS8tJI3Y54IHG1RaampaIUDxeqOcs5aR7XTHda6FTVTwrlW2kbRRnAtldCU5Q3ISpwUr_e6ITpzY70ZwO_iYjA30ZxeXM4No7XQgukMz_dwN8C1WUW_hLjZZewuhrgwEPO-ejTAuLagXO2YrKClTS7YyRa0rVArgVlL7LWmsILNd-j7O0FGzdZUszfV5EbNzlQjc9a7fdZqapfY2exAhP5BKw9fgr_Ko6xNluKNUtuBX90qxOHbhGk0S58s9j0EHKZkBOdS11QyltGXf6HXwxRDtmNLKc3rqtkKvrjf0l0vvz9WBvgesHFIKaL7v0Fv15MyHBYY_9T-R9YvvY_vsg |
| Cites_doi | 10.1016/j.celrep.2019.12.056 10.1158/0008-5472.CAN-16-2976 10.1091/mbc.e14-04-0916 10.3389/fonc.2020.00281 10.3390/cells8090957 10.1111/iep.12212 10.3390/cancers14174068 10.1016/j.celrep.2023.113124 10.1016/j.ccell.2018.08.001 10.1126/scitranslmed.aav0936 10.3389/fmolb.2022.836417 10.1038/s41588-022-01047-6 10.1038/s41419-022-05146-4 10.1016/j.molcel.2011.11.032 10.1021/ja00738a045 10.1038/s41467-021-26502-6 10.1038/modpathol.2011.161 10.1016/j.crstbi.2020.05.001 10.1158/1078-0432.CCR-10-1725 10.1016/j.ejmech.2022.114542 10.1074/jbc.M114.635250 10.3389/fcell.2022.1115903 10.1007/s12094-024-03621-2 10.1016/j.cell.2018.03.041 10.1038/nmeth.1314 10.2217/pgs.11.84 10.1074/jbc.RA117.000698 10.1186/s12943-024-02071-2 10.1016/j.cell.2010.02.027 10.1016/j.canlet.2015.10.010 10.4161/epi.3.5.6868 10.1038/s41571-021-00565-2 10.1007/BF02673749 10.1016/j.drup.2017.10.003 10.1038/s42003-021-02405-6 10.4143/crt.2022.1450 10.1038/s41467-018-05729-w 10.1016/j.ajhg.2016.11.011 10.1073/pnas.0800970105 10.1097/FPC.0b013e3283385a1c 10.1038/nrd1984 10.1038/s41571-023-00815-5 10.1038/s41420-024-02193-y 10.1158/2159-8290.CD-19-1493 10.1016/j.bbamcr.2015.04.014 10.1158/0008-5472.CAN-3263-2 10.1182/blood-2010-04-277269 10.1016/j.stem.2015.06.002 10.1038/s41591-019-0638-5 10.1128/MCB.01297-08 10.1074/jbc.M115.643189 10.2174/1389450116666150330113506 10.1038/nature05473 10.3389/fonc.2020.561936 10.1158/0008-5472.CAN-04-4133 10.4161/epi.26792 10.1016/j.csbj.2021.07.014 10.1038/s41388-021-02039-2 10.1038/s41419-024-06422-1 10.1152/ajpcell.00283.2017 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA ACYCR |
| DOI | 10.1038/s12276-025-01466-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 2092-6413 |
| EndPage | 1307 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10738318 oai_doaj_org_article_a128ca6f7f154ab09010d5ba8c4e863e 10.1038/s12276-025-01466-5 PMC12229664 40583060 10_1038_s12276_025_01466_5 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Türkiye Bilimsel ve Teknolojik Araştirma Kurumu (Scientific and Technological Research Council of Turkey) grantid: 221S419; 221S419 funderid: https://doi.org/10.13039/501100004410 – fundername: Türkiye Bilimsel ve Teknolojik Araştirma Kurumu (Scientific and Technological Research Council of Turkey) grantid: 221S419 |
| GroupedDBID | --- 0R~ 29G 2WC 5-W 53G 5GY 7X7 87B 88E 8FE 8FH 8FI 8FJ 8JR 9ZL AAJSJ AASML ABUWG ACGFO ACGFS ACPRK ACYCR ADBBV AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI C1A C6C CCPQU DIK DU5 E3Z EBLON EBS EF. EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE LK8 M1P M7P NAO OK1 OVT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT TR2 UKHRP W2D XSB AAYXX CITATION PJZUB PPXIY PQGLB PUEGO CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AARCD AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c529t-64af0be685803b3fa617d0221bf08f8de78b37163ffb5c9609328563801025543 |
| IEDL.DBID | C6C |
| ISSN | 2092-6413 1226-3613 |
| IngestDate | Sun Jul 27 03:10:32 EDT 2025 Wed Aug 27 01:28:36 EDT 2025 Tue Aug 19 23:33:00 EDT 2025 Tue Sep 30 17:02:03 EDT 2025 Fri Sep 05 15:45:23 EDT 2025 Wed Aug 13 06:21:00 EDT 2025 Mon Jul 21 06:01:51 EDT 2025 Wed Oct 01 05:48:39 EDT 2025 Fri Jul 04 01:26:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c529t-64af0be685803b3fa617d0221bf08f8de78b37163ffb5c9609328563801025543 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1111-7752 0000-0001-5288-3077 0000-0003-3646-2613 0000-0002-2372-9158 0000-0002-8936-3267 0000-0003-1033-1797 0000-0001-6981-6962 0000-0002-0437-6385 |
| OpenAccessLink | https://www.nature.com/articles/s12276-025-01466-5 |
| PMID | 40583060 |
| PQID | 3226827494 |
| PQPubID | 2041975 |
| PageCount | 14 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10738318 doaj_primary_oai_doaj_org_article_a128ca6f7f154ab09010d5ba8c4e863e unpaywall_primary_10_1038_s12276_025_01466_5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12229664 proquest_miscellaneous_3225870511 proquest_journals_3226827494 pubmed_primary_40583060 crossref_primary_10_1038_s12276_025_01466_5 springer_journals_10_1038_s12276_025_01466_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-06-01 |
| PublicationDateYYYYMMDD | 2025-06-01 |
| PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: United States – name: Seoul |
| PublicationTitle | Experimental & molecular medicine |
| PublicationTitleAbbrev | Exp Mol Med |
| PublicationTitleAlternate | Exp Mol Med |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Springer Nature B.V Nature Publishing Group 생화학분자생물학회 |
| Publisher_xml | – name: Nature Publishing Group UK – name: Springer Nature B.V – name: Nature Publishing Group – name: 생화학분자생물학회 |
| References | X Cai (1466_CR59) 2015; 17 T Viita (1466_CR35) 2022; 10 LD Cripe (1466_CR9) 2010; 116 L You (1466_CR53) 2015; 290 A Cribbs (1466_CR30) 2018; 293 C Kim (1466_CR12) 2018; 173 T Risom (1466_CR14) 2018; 9 B Gyorffy (1466_CR39) 2021; 19 LM Hodges (1466_CR32) 2011; 21 RJ Kelly (1466_CR10) 2011; 17 J Marsolier (1466_CR19) 2022; 54 L Desiderato (1466_CR23) 1997; 23 XJ Yang (1466_CR61) 2015; 1853 M Nedeljkovic (1466_CR2) 2019; 8 KG Chen (1466_CR24) 2005; 65 X Mu (1466_CR51) 2024; 10 A Li (1466_CR25) 2016; 97 K Reed (1466_CR26) 2008; 3 AG Manjon (1466_CR28) 2023; 42 BD Lehmann (1466_CR18) 2021; 12 JI Lai (1466_CR7) 2020; 10 M Yu (1466_CR60) 2012; 45 MC Wani (1466_CR3) 1971; 93 B Ruprecht (1466_CR43) 2017; 77 SA Ali (1466_CR58) 2008; 105 NM Almansour (1466_CR1) 2022; 9 MA Desbats (1466_CR42) 2020; 10 BA Weaver (1466_CR4) 2014; 25 L Xu (1466_CR27) 2021; 68 BJ Klein (1466_CR37) 2014; 9 I Genovese (1466_CR33) 2017; 32 CL Cheng (1466_CR55) 2021; 4 G Szakacs (1466_CR6) 2006; 5 K Reed (1466_CR40) 2011; 12 G Zu (1466_CR56) 2022; 14 C Cherif (1466_CR48) 2022; 41 SH Lee (1466_CR50) 2023; 55 JA Seoane (1466_CR22) 2019; 25 H Cui (1466_CR34) 2015; 16 VS Jones (1466_CR44) 2016; 1865 A Salvati (1466_CR63) 2024; 23 K Yan (1466_CR54) 2017; 100 L You (1466_CR52) 2015; 290 EK Schmidt (1466_CR31) 2009; 6 O Yedier-Bayram (1466_CR29) 2022; 13 S Wu (1466_CR47) 2024; 27 G Deblois (1466_CR17) 2020; 10 Y Chen (1466_CR46) 2018; 315 Z Chen (1466_CR8) 2016; 370 B Cevatemre (1466_CR62) 2024; 15 Y Pu (1466_CR15) 2023; 20 S Yomtoubian (1466_CR16) 2020; 30 C Dravis (1466_CR21) 2018; 34 A Katagiri (1466_CR49) 2012; 25 JO Obi (1466_CR36) 2020; 2 DW Young (1466_CR57) 2007; 445 G Bianchini (1466_CR5) 2022; 19 M Ullah (1466_CR38) 2008; 28 X Zhou (1466_CR41) 2020; 26 K Engle (1466_CR11) 2022; 239 GV Echeverria (1466_CR13) 2019; 11 SV Sharma (1466_CR20) 2010; 141 K Yasui (1466_CR45) 2004; 64 |
| References_xml | – volume: 30 start-page: 755 year: 2020 ident: 1466_CR16 publication-title: Cell Rep. doi: 10.1016/j.celrep.2019.12.056 – volume: 77 start-page: 1842 year: 2017 ident: 1466_CR43 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2976 – volume: 25 start-page: 2677 year: 2014 ident: 1466_CR4 publication-title: Mol. Biol. Cell doi: 10.1091/mbc.e14-04-0916 – volume: 10 start-page: 281 year: 2020 ident: 1466_CR42 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00281 – volume: 8 start-page: 957 year: 2019 ident: 1466_CR2 publication-title: Cells doi: 10.3390/cells8090957 – volume: 97 start-page: 412 year: 2016 ident: 1466_CR25 publication-title: Int J. Exp. Pathol. doi: 10.1111/iep.12212 – volume: 14 start-page: 4068 year: 2022 ident: 1466_CR56 publication-title: Cancers doi: 10.3390/cancers14174068 – volume: 42 year: 2023 ident: 1466_CR28 publication-title: Cell Rep. doi: 10.1016/j.celrep.2023.113124 – volume: 34 start-page: 466 year: 2018 ident: 1466_CR21 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.08.001 – volume: 11 start-page: eaav0936 year: 2019 ident: 1466_CR13 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aav0936 – volume: 9 start-page: 836417 year: 2022 ident: 1466_CR1 publication-title: Front. Mol. Biosci. doi: 10.3389/fmolb.2022.836417 – volume: 54 start-page: 459 year: 2022 ident: 1466_CR19 publication-title: Nat. Genet. doi: 10.1038/s41588-022-01047-6 – volume: 13 year: 2022 ident: 1466_CR29 publication-title: Cell Death Dis. doi: 10.1038/s41419-022-05146-4 – volume: 26 year: 2020 ident: 1466_CR41 publication-title: Med Sci. Monit. – volume: 45 start-page: 330 year: 2012 ident: 1466_CR60 publication-title: Mol. Cell doi: 10.1016/j.molcel.2011.11.032 – volume: 93 start-page: 2325 year: 1971 ident: 1466_CR3 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja00738a045 – volume: 12 year: 2021 ident: 1466_CR18 publication-title: Nat. Commun. doi: 10.1038/s41467-021-26502-6 – volume: 25 start-page: 282 year: 2012 ident: 1466_CR49 publication-title: Mod. Pathol. doi: 10.1038/modpathol.2011.161 – volume: 2 start-page: 104 year: 2020 ident: 1466_CR36 publication-title: Curr. Res. Struct. Biol. doi: 10.1016/j.crstbi.2020.05.001 – volume: 17 start-page: 569 year: 2011 ident: 1466_CR10 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-10-1725 – volume: 239 start-page: 114542 year: 2022 ident: 1466_CR11 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2022.114542 – volume: 290 start-page: 7114 year: 2015 ident: 1466_CR52 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M114.635250 – volume: 68 start-page: 593 year: 2021 ident: 1466_CR27 publication-title: Acta Biochim. Pol. – volume: 10 start-page: 1115903 year: 2022 ident: 1466_CR35 publication-title: Front. Cell Dev. Biol. doi: 10.3389/fcell.2022.1115903 – volume: 27 start-page: 507 year: 2024 ident: 1466_CR47 publication-title: Clin. Transl. Oncol doi: 10.1007/s12094-024-03621-2 – volume: 173 start-page: 879 year: 2018 ident: 1466_CR12 publication-title: Cell doi: 10.1016/j.cell.2018.03.041 – volume: 6 start-page: 275 year: 2009 ident: 1466_CR31 publication-title: Nat. Methods doi: 10.1038/nmeth.1314 – volume: 12 start-page: 1465 year: 2011 ident: 1466_CR40 publication-title: Pharmacogenomics doi: 10.2217/pgs.11.84 – volume: 293 start-page: 2422 year: 2018 ident: 1466_CR30 publication-title: J. Biol. Chem. doi: 10.1074/jbc.RA117.000698 – volume: 23 year: 2024 ident: 1466_CR63 publication-title: Mol. Cancer doi: 10.1186/s12943-024-02071-2 – volume: 141 start-page: 69 year: 2010 ident: 1466_CR20 publication-title: Cell doi: 10.1016/j.cell.2010.02.027 – volume: 370 start-page: 153 year: 2016 ident: 1466_CR8 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.10.010 – volume: 3 start-page: 270 year: 2008 ident: 1466_CR26 publication-title: Epigenetics doi: 10.4161/epi.3.5.6868 – volume: 19 start-page: 91 year: 2022 ident: 1466_CR5 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-021-00565-2 – volume: 23 start-page: 391 year: 1997 ident: 1466_CR23 publication-title: Somat. Cell Mol. Genet. doi: 10.1007/BF02673749 – volume: 32 start-page: 23 year: 2017 ident: 1466_CR33 publication-title: Drug Resist. Updat. doi: 10.1016/j.drup.2017.10.003 – volume: 4 start-page: 888 year: 2021 ident: 1466_CR55 publication-title: Commun. Biol. doi: 10.1038/s42003-021-02405-6 – volume: 55 start-page: 1291 year: 2023 ident: 1466_CR50 publication-title: Cancer Res. Treat. doi: 10.4143/crt.2022.1450 – volume: 9 year: 2018 ident: 1466_CR14 publication-title: Nat. Commun. doi: 10.1038/s41467-018-05729-w – volume: 100 start-page: 91 year: 2017 ident: 1466_CR54 publication-title: Am. J. Hum. Genet doi: 10.1016/j.ajhg.2016.11.011 – volume: 105 start-page: 6632 year: 2008 ident: 1466_CR58 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0800970105 – volume: 21 start-page: 152 year: 2011 ident: 1466_CR32 publication-title: Pharmacogenet. Genomics doi: 10.1097/FPC.0b013e3283385a1c – volume: 5 start-page: 219 year: 2006 ident: 1466_CR6 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd1984 – volume: 20 start-page: 799 year: 2023 ident: 1466_CR15 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-023-00815-5 – volume: 10 start-page: 422 year: 2024 ident: 1466_CR51 publication-title: Cell Death Discov. doi: 10.1038/s41420-024-02193-y – volume: 10 start-page: 1312 year: 2020 ident: 1466_CR17 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-19-1493 – volume: 1853 start-page: 1818 year: 2015 ident: 1466_CR61 publication-title: Biochim Biophys. Acta doi: 10.1016/j.bbamcr.2015.04.014 – volume: 64 start-page: 1403 year: 2004 ident: 1466_CR45 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-3263-2 – volume: 116 start-page: 4077 year: 2010 ident: 1466_CR9 publication-title: Blood doi: 10.1182/blood-2010-04-277269 – volume: 17 start-page: 165 year: 2015 ident: 1466_CR59 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2015.06.002 – volume: 25 start-page: 1721 year: 2019 ident: 1466_CR22 publication-title: Nat. Med. doi: 10.1038/s41591-019-0638-5 – volume: 28 start-page: 6828 year: 2008 ident: 1466_CR38 publication-title: Mol. Cell Biol. doi: 10.1128/MCB.01297-08 – volume: 290 start-page: 11349 year: 2015 ident: 1466_CR53 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M115.643189 – volume: 16 start-page: 1356 year: 2015 ident: 1466_CR34 publication-title: Curr. Drug Targets doi: 10.2174/1389450116666150330113506 – volume: 445 start-page: 442 year: 2007 ident: 1466_CR57 publication-title: Nature doi: 10.1038/nature05473 – volume: 10 start-page: 561936 year: 2020 ident: 1466_CR7 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.561936 – volume: 65 start-page: 9388 year: 2005 ident: 1466_CR24 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-4133 – volume: 1865 start-page: 255 year: 2016 ident: 1466_CR44 publication-title: Biochim. Biophys. Acta – volume: 9 start-page: 186 year: 2014 ident: 1466_CR37 publication-title: Epigenetics doi: 10.4161/epi.26792 – volume: 19 start-page: 4101 year: 2021 ident: 1466_CR39 publication-title: Comput. Struct. Biotechnol. J. doi: 10.1016/j.csbj.2021.07.014 – volume: 41 start-page: 125 year: 2022 ident: 1466_CR48 publication-title: Oncogene doi: 10.1038/s41388-021-02039-2 – volume: 15 year: 2024 ident: 1466_CR62 publication-title: Cell Death Dis. doi: 10.1038/s41419-024-06422-1 – volume: 315 start-page: C225 year: 2018 ident: 1466_CR46 publication-title: Am. J. Physiol. Cell Physiol. doi: 10.1152/ajpcell.00283.2017 |
| SSID | ssj0025474 |
| Score | 2.4105065 |
| Snippet | Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary treatment... Abstract Triple-negative breast cancer (TNBC) is a particularly aggressive and frequently recurring form of breast cancer, where chemotherapy is the primary... |
| SourceID | nrf doaj unpaywall pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1294 |
| SubjectTerms | 13/1 13/109 13/31 13/89 14/63 38/22 38/91 42 42/47 631/337/176 631/67/1059/99 631/67/1347 692/699/67/1059/2326 96/98 ABC transporters Antineoplastic Agents, Phytogenic - pharmacology Apoptosis Artificial intelligence ATP Binding Cassette Transporter, Subfamily B - genetics Biomedical and Life Sciences Biomedicine Breast cancer Cancer Cancer therapies Cell Line, Tumor Cell viability Chemoresistance Chemotherapy Chromatin Chromatin - genetics Chromatin - metabolism DNA methylation DNA structure Drug dosages Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Epigenesis, Genetic Epigenetics Female Gene Expression Regulation, Neoplastic - drug effects Histone acetyltransferase Humans Medical Biochemistry Molecular Medicine Multidrug resistance Nuclear Proteins - antagonists & inhibitors Nuclear Proteins - genetics Nuclear Proteins - metabolism Paclitaxel Paclitaxel - pharmacology Phenotypes Proteins Stem Cells Toxicity Transcriptomes Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - metabolism Triple Negative Breast Neoplasms - pathology Tumors 생화학 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDzwOCFoegYKMQFyo1Tz82mOLWBWkIoRaqTfLduKy6uJUu1lg_wM_mhknu3QFAg6cIiXOy_5m_I09_kzICzEKgTtRMClqybjXgVnlOCtHtbVwXlVpF4Xj9_LolL87E2dXtvrCnLBeHrivuH0LDtRbGVSAzt66HNMJauGs9rzRsmrQ-0I3tgqmhlBLcMWHJTJ5pffnRVkqTLbFRDUuJRMb3VBS64fOJc7C74jmr_mS60nTW-TGIl7a5Vc7nV7pl8Z3yO2BUNKD_kfukmtN3CY7BxGC6c9L-pKmFM80dr5Nrh8PM-k75Duq4iJbjSy0fjFvagpQwhWN1Maa-kFHgIJXwUiXTtKC3rCkhx8_jAtq59TSPosc117RL4spylenTNslnUR6Yr-1UwaxPPLT2NFuhiP6LDbnSWmcOkyG76hH0M3ukdPxm5PXR2zYmYF5UY46JrkNuWtQuz6vXBUs8KAa2EDhQq6DrhulXQWRWBWCEx5F7apSCzB1VLADAlPdJ1uxjc1DQqXMobznwNws98rBI73zjeI-KBVGdUZerRrKXPYCHCZNnFfa9M1q4JEmNasRGTnEtlyXRPHsdAIgZQZImb9BKiPPAQnmwk_S_Xg8b83FzECI8RberCCqL3RGdldIMYPdzw24R6kh0B_xjDxbXwaLxWkYG5t2kcoI8JLAdDPyoAfW-nuBPmsI4vKM6A3IbfzQ5pU4-ZRUwQvcmV1KePHeCp0_v-tPNba3RvA_VPCj_1HBj8nNMtkiDmbtkq1utmieALfr3NNkxj8ADThJyQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFLVgSHw8INgYBAYyAvHCrCWN7bhPaENUA2kIoU3qm2U7calWnJKmQP8DP5p73bSlAk08RXKcT597fa59fUzIS9H3nluRMSlKybhTnpnCctbrl8ZAeZHHXRTOPsrTC_5hKIbdgNusS6tc-cToqMva4Rj5EQBPKgih-vzN9BvDXaNwdrXbQuM6uZEBVUFUF8NNwCV4VGHO4FKWQ7_VLZpJc3U0g8IC028xdY1LycRWxxT1-6G7CY3_F_X8O4NyPY16h9yah6lZ_DCTyR891eAeudtRTHq8xMR9cq0Ku2TvOEB4_XVBX9GY9BlH03fJzbNubn2P_EKdXOSvgfnazWdVSQFcuMaRmlBS1ykLUPAzGPvScVzi6xf05POnQUbNjBq6zCvH1Vj0-3yCgtYx93ZBx4Gem5_1hEF0j4w1tLRtcIyfhWoUtcepxfT4ljqEYfOAXAzenb89Zd1eDcyJXr9lkhuf2grV7NPc5t4AMyqBH2TWp8qrsiqUzSE2y723wqHMXd5TAowfNe2A0uT7ZCfUoXpEqJQp1HccuJzhrrBwS2ddVXDni8L3y4S8XjWUni4lOXScSs-VXjarhlvq2KxaJOQE23JdE-W0Y0HdjHRnndpAL-2M9IUHRmlsijkrpbBGOV4pmVcJeQFI0JduHK_H46jWl42GoOM9PLmAOD9TCTlYIUV3nmCmN7hNyPP1abBhnJgxoarnsY4AvwncNyEPl8Bavy8QagVhXZoQtQW5rQ_aPhPGX6JOeIZ7tUsJDz5coXPzXlf9scM1gv_jBz---qufkNu9aGU4cHVAdtpmXj0FHtfaZ9FYfwO1bELI priority: 102 providerName: ProQuest |
| Title | Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer |
| URI | https://link.springer.com/article/10.1038/s12276-025-01466-5 https://www.ncbi.nlm.nih.gov/pubmed/40583060 https://www.proquest.com/docview/3226827494 https://www.proquest.com/docview/3225870511 https://pubmed.ncbi.nlm.nih.gov/PMC12229664 https://www.nature.com/articles/s12276-025-01466-5.pdf https://doaj.org/article/a128ca6f7f154ab09010d5ba8c4e863e https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003227360 |
| UnpaywallVersion | publishedVersion |
| Volume | 57 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Experimental and Molecular Medicine, 2025, 57(0), , pp.1294-1307 |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: HH5 dateStart: 19960101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: DOA dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: 5-W dateStart: 19970101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: RPM dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVAQT databaseName: Springer Nature - nature.com Journals - Fully Open Access customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: NAO dateStart: 19960301 isFulltext: true titleUrlDefault: https://www.nature.com/siteindex/index.html providerName: Nature Publishing – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: AAJSJ dateStart: 19970301 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 2092-6413 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025474 issn: 2092-6413 databaseCode: C6C dateStart: 19960301 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZ2kbg8INi4BEZlBOKFRcvFtz621apRadM0Nmlvlu3EpVpxprQF-h_40Ry7aaBiQvAUKXEcOz62v2N_5zNC72jXWqJpGjNasJgYYWPFNYmzbqEU3Od5OEXh9IydXJHRNb3eQtk6FiaQ9oOkZRim1-ywo1maZdzTZT3VjDAW0220K3ieehrfgA1aJ4sSTprgmCQXd7y3MQEFnX6YVlxt74KYfzIl2-3Sh-j-wt2q5Tc1nf42Iw0fo0cNlMS9VeGfoK3S7aH9HtSr-rLE73Egd4ZV8z1077TZQ99HP7wersepLraVWczKAoMR-VhGrFyBTaMggGE88T4unoRQXrvE_YvzYYrVDCu84o_7qCv8dTH1wtWBY7vEE4cv1fdqGoMX75Gpm-N57dfyY1eOg8Y41p4GP8fGm1v9FF0Njy8HJ3FzJkNsaNadx4wom-jSq9Ynuc6tAgRUAA5ItU2EFUXJhc7BB8ut1dR4Obs8ExQ6udeuA-iSP0M7rnLlC4QZSyC9IYDZFDFcQ5ZGm5ITYzm33SJCH9YNJW9X0hsybJnnQq6aVUKWMjSrpBHq-7ZsU3rZ7HCjqseyMSOpYDY2illuATkqnXhuSkG1EoaUguVlhN6CJcgbMwnv--u4kje1BOfiI3yZgz-figgdrC1FNj1-JmFgZAJc_C6J0Jv2MfRVvwGjXFktQhoK4yNg3Ag9XxlWW14AzgLctyRCYsPkNiq0-cRNPgc98NSfyc4YfPhwbZ2_yvW3P3bYWvA__OCX_5f7K_QgC73OL1gdoJ15vShfA36b6w7a5te8g3Z7vdGnEVz7x2fnF53QjTthTeQn85ZDpw |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkBg8INi4BAYYcXlh1tLacdIHhDZg2thFCG1S34zt2KNacUbaMvof-C38Rs5x044KNPGyp0qOmzjx53PxOf4OIc-zjvfCZC0ms1IyYQvPdG4Ea3dKraE957GKwv6B3D4SH7pZd4H8mp6FwbTKqUyMgrqsLO6RrwPwZAEuVEe8Of3GsGoURlenJTQmsNh14zNw2Qavd97B_L5ot7feH77dZk1VAWazdmfIpNA-NQ5511NuuNegw0vQZC3j08IXpcsLw8GL4N6bzCIhG28XGcAU2ddA-XK47xVyVfBUIFd_3j138DIRWZ9bMFTGQU82h3RSXqwPoDHHdF9MlRNSsmxOEcZ6AaDeQu3_Zer-nbE5C9veIEujcKrHZ7rf_0Mzbt0iNxuTlm5MMHibLLiwTFY2ArjzX8f0JY1JpnH3fplc229i-SvkJ_Lyor0cmK_saOBKCmDGM5VUh5LahsmAglxDX5v24pFiP6abnz5utageUE0neex4-ot-H_WRQDvm-o5pL9BD_aPqs9oN0EIOQzqsMabAgjuOXOfUYDr-kFqEfX2HHF3KLN4li6EK7j6hUqbQ3wqwHbWwuYFbWmNdLqzPc98pE_JqOlHqdEIBomLonhdqMq0KbqnitKosIZs4l7OeSN8dG6r6WDXSQGmwCqyWPvdgwWqTYo5MmRldWOEKyV1CngES1Intxf_j73GlTmoFTs4OPDnnBcjihKxOkaIayTNQ5-skIU9nl0FmYCBIB1eNYp8M5DTY2gm5NwHWbLxgwBfgRqYJKeYgN_dC81dC70vkJW9hbXgp4cFrU3Sej-uiL7Y2Q_B_fOAHF7_1E7K0fbi_p_Z2DnYfkuvtuOJw02yVLA7rkXsENuTQPI4Ll5LPly0pfgP9An02 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKkQocELQ8FgoY8bhQq5t41-scEGopEaW0qlAr9WZsr12iBm_ZJJT8B34Rv44ZZ5MSgSouPUXyOl57ZzwPz_gbQp7nHe8zk7eYyEvBMis904XJWLtTag3tBY9VFHb3xPvD7MNRfrRAfk3vwmBa5VQmRkFdVhbPyNeB8YQEF6qTrfsmLWJ_q_vm9BvDClIYaZ2W05iwyI4bn4H7Nni9vQW0ftFud98dvH3PmgoDzObtzpCJTPvUOMRgT7nhXoM-L0GrtYxPpZelK6Th4FFw701uEZyNt2UOLItIbKCIOYx7hVyFBXFMJyuOzp29PIsI0C2YNuOgM5sLOymX6wNoLDD1F9PmMiFYPqcUY-0AUHWh9v8ye__O3pyFcG-Qa6Nwqsdnut__Q0t2b5GbjXlLNyb8eJssuLBMVjYCuPZfx_QljQmn8SR_mSztNnH9FfITMXrRdg7MV3Y0cCUFxsb7lVSHktoG1YCCjEO_m_bi9WI_ppuf9rstqgdU00lOO94Eo99HfQTTjnm_Y9oL9ED_qPqsdgO0lsOQDmuML7DgjiPuOTWYmj-kFrdAfYccXgoV75LFUAV3n1AhUuhvM7AjdWYLA0NaY12RWV8UvlMm5NWUUOp0AgeiYhifSzUhq4IhVSSryhOyibSc9UQo79hQ1ceqkQxKg4VgtfCFB2tWmxTzZcrcaGkzJwV3CXkGnKBObC_-H3-PK3VSK3B4tuHNBZcglxOyOuUU1UihgTrfMwl5OnsM8gODQjq4ahT75CCzwe5OyL0JY83mC8a8BJcyTYicY7m5Bc0_Cb0vEaO8hXXihYAXr02583xeF32xtRkH_8cHfnDxqp-QJZAR6uP23s5Dcr0dNxyen62SxWE9co_AnByax3HfUvL5sgXFb0uAgXE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chromatin-focused+genetic+and+chemical+screens+identify+BRPF1+as+a+targetable+vulnerability+in+Taxol-resistant+triple-negative+breast+cancer&rft.jtitle=Experimental+%26+molecular+medicine&rft.au=Yedier-Bayram%2C+Ozlem&rft.au=Cing%C3%B6z%2C+Ahmet&rft.au=Yilmaz%2C+Ebru&rft.au=Aksu%2C+Ali+Cenk&rft.date=2025-06-01&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2092-6413&rft.volume=57&rft.issue=6&rft.spage=1294&rft.epage=1307&rft_id=info:doi/10.1038%2Fs12276-025-01466-5&rft.externalDocID=10_1038_s12276_025_01466_5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-6413&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-6413&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-6413&client=summon |